Erratum: Advances in Oncology 5.1.
- Published in:
- 2010
- Publication type:
- Correction Notice
Works matching IS 17505925 AND DT 2010 AND VI 5 AND IP 2
Results: 10
1
2
Neratinib, an irreversible erbB receptor tyrosine kinase inhibitor, in patients with advanced erbB2-positive breast cancer.
- Published in:
- Advances in Oncology, 2010, v. 5, n. 2, p. 21
- By:
- Publication type:
- Article
3
Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.
- Published in:
- 2010
- By:
- Publication type:
- Opinion
4
Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
- Published in:
- 2010
- By:
- Publication type:
- Opinion
5
Sutent Satellite Symposium: held parallel to the 15th Annual Scientific Meeting of Alexandria Clinical Oncology Department (ACOD) Alexandria, Egypt, 14-16 April 2010.
- Published in:
- 2010
- Publication type:
- Proceeding
6
IMPAKT Breast Cancer Conference.
- Published in:
- 2010
- By:
- Publication type:
- Conference Paper/Materials
7
7th European Breast Cancer Conference (EBCC 7).
- Published in:
- 2010
- By:
- Publication type:
- Conference Paper/Materials
8
American Society of Clinical Oncology (ASCO).
- Published in:
- 2010
- By:
- Publication type:
- Conference Paper/Materials
9
The Torisel trials in advanced renal cell carcinoma.
- Published in:
- Advances in Oncology, 2010, v. 5, n. 2, p. 5
- By:
- Publication type:
- Article
10
Therapeutic mammoplasty: a fusion of oncological and aesthetic breast surgery.
- Published in:
- Advances in Oncology, 2010, v. 5, n. 2, p. 1
- By:
- Publication type:
- Article